Ads
related to: regeneron pharmaceuticals
Search results
... for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) - ...
Benzinga· 4 days agoRegeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...
Pipeline Moves: Phase III completion for Corcept’s relaorilant
Clinical Trials Arena via Yahoo Finance· 4 days agoPhase II trial of Regeneron‘s mibavademab completes Regeneron Pharmaceuticals’s mibavademab saw its...
Regeneron CEO Leonard Schleifer sells over $35 million in company stock By Investing.com
Investing.com· 1 day agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) has reported several transactions by its...
Regeneron shares rise on Evercore ISI Outperform rating By Investing.com
Investing.com· 3 days agoOn Monday, Evercore ISI initiated coverage on Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc....
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary...
JD Supra· 7 days agoAs we previously reported, the Judicial Panel on Multidistrict Litigation recently granted Regeneron Pharmaceutical’s (“Regeneron”) motion to establish ...
On the Move: May 16, 2024
Nashville Post· 11 hours agoHarrow, ThriveAP, Titan Cloud announce updates
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Zacks· 7 days agoMaking its debut on 06/23/2005, smart beta exchange traded fund Invesco Biotechnology & Genome ETF (PBE Quick QuotePBE - Free Report) provides investors broad exposure to the Health Care ETFs ...
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Zacks via Yahoo Finance· 7 days agoWhen you look at individual holdings, Neurocrine Biosciences Inc (NBIX) accounts for about 5.26% of...
FDA considers Dupixent for adolescent sinusitis treatment By Investing.com
Investing.com· 4 days agoThe U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental...
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Zacks· 7 days agoIntellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.